CAS 849758-52-7 Bevasiranib sodium

Meet our team at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in October 6-9 for expert consultation on your drug discovery projects. Shoot an email to arrange an in-person meeting.

Bevasiranib sodium

Bevasiranib sodium is a small interfering RNA (siRNA) therapeutic designed to treat ocular diseases, particularly age-related macular degeneration (AMD). By targeting and silencing the mRNA for vascular endothelial growth factor (VEGF), bevasiranib sodium aims to inhibit the production of VEGF, a key protein involved in the formation of abnormal blood vessels and increased vascular permeability in the retina, which are characteristic of AMD.

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Catalog

BRP-02088

Synonyms

RNA, (A-C-C-U-C-A-C-C-A-A-G-G-C-C-A-G-C-A-C-dT-dT), eicosasodium salt, complex with RNA (G-U-G-C-U-G-G-C-C-U-U-G-G-U-G-A-G-G-U-dT-dT) eicosasodium salt (1:1); Cand 5

CAS

849758-52-7

Storage

Store at -20 °C

Sequence

RNA, (accucaccaaggccagcactt), complex with RNA (gugcuggccuuggugaggutt) (1:1), sodium salt

Related CAS

959961-96-7 (free acid)

Bevasiranib sodium - CAS 849758-52-7

Bevasiranib sodium